Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625062 · ClinicalTrials.gov registry record · Phase 1
Comparing Traditional and Biofeedback Telepractice Treatment for Residual Speech Errors
A Phase 1 study, sponsored by New York University.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04625062: Completed Phase 1 study, sponsored by New York University.
NCT04625062 is a Phase 1 study that has completed, run by New York University. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04625062, a Phase 1 study, has completed, sponsored by New York University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study aims to evaluate the relative efficacy of biofeedback and traditional treatment for residual speech errors when both are delivered via telepractice. In a single-case randomization design, up to eight children with RSE will receive both visual-acoustic biofeedback and traditional treatment via telepractice. Acoustic measures of within-session change will be compared across sessions randomly assigned to each condition. It is hypothesized that participants will exhibit a clinically significant overall treatment response and that short-term measures of change will indicate that biofeedback is associated with larger increments of progress than traditional treatment.
Primary Outcome
To assess /r/ production accuracy, participants read probe lists eliciting 25 utterances of /r/ in various phonetic contexts at the start and end of each treatment session. Recorded probe words are presented in randomized order for binary rating (correct/incorrect) by naive listeners who are blind to treatment condition and time point; the accuracy of each token is quantified as the percentage of "correct" ratings across 9 blinded listeners. We then compute the mean percent correct ratings for e
Interventions
- BEHAVIORAL Visual-acoustic biofeedback
- BEHAVIORAL Motor-based treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2021-03-18 |
| Phase | Phase 1 |
What the finished NCT04625062 record still lists
NCT04625062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Visual-acoustic biofeedback is the first listed.
NCT04625062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04625062 about?
NCT04625062 is a clinical study titled "Comparing Traditional and Biofeedback Telepractice Treatment for Residual Speech Errors". This study aims to evaluate the relative efficacy of biofeedback and traditional treatment for residual speech errors when both are delivered via telepractice. In a single-case randomization design, up to eight children with RSE will receive both visual-acoustic biofeedback and traditional treatment...
What is the current status of trial NCT04625062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-09-01. Estimated completion is 2021-03-18.
What interventions are being tested in trial NCT04625062?
The interventions under investigation include: Visual-acoustic biofeedback (BEHAVIORAL), Motor-based treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT04625062?
This trial is sponsored by New York University, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04625062's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI